ClinicalTrials.gg

Program

acasunlimab

Also written as “Acasunlimab”, “Acasunlimab in combination with docetaxel (in a single expansion cohort)” and “Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)”.

Its studies are mostly in Lung Neoplasms · Melanoma · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by Genmab.

Furthest: phase 3, since Oct 8, 20246 company-led studies, 1 open or runningNext primary completion: Jul 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genmab61 open or runningphase 3since Oct 8, 2024Apr 11, 2019Jul 30, 2027phase 3 · NCT06635824

Also a collaborator on its studies: Merck and BioNTech.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 11, 2019First study: phase 2 study in Solid TumorsFirst studyNCT03917381 · 429 enrolled · United States, Czechia, Georgia and more
  2. May 11, 2021Phase 1 study in Solid TumorNCT04937153 · 18 enrolled · Japan
  3. Nov 1, 2021Phase 2 study in Non Small Cell Lung Cancer MetastaticNCT05117242 · 125 enrolled · United States, France, Germany and more
  4. Sep 14, 2023Phase 2 study in Advanced Endometrial CancerNCT06046274 · United States, Belgium, Denmark and more
  5. Oct 8, 2024Phase 3 study in Lung NeoplasmsNCT06635824 · 191 enrolled · United States, Argentina, Australia and more
  6. May 14, 2025Phase 2 study in MelanomaNCT06984328 · 1 enrolled · United States, Puerto Rico

Ahead

  1. Jul 30, 2027Primary completion: phase 3 study in Lung NeoplasmsNCT06635824

TargetBeta

“A recombinant, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
Anti-CD137/PD-L1 Bispecific Antibody FS222Sino Biopharmaceuticalphase 11

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06984328Melanoma · United States, Puerto Rico2TerminatedMay 15, 20261
NCT06635824Lung Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJul 30, 2027191
NCT06046274Advanced Endometrial Cancer · United States, Belgium, Denmark and more2WithdrawnApr 1, 20280
NCT05117242Non Small Cell Lung Cancer Metastatic · United States, France, Germany and more2TerminatedDec 2, 2024125
NCT04937153Solid Tumor · Japan1CompletedOct 1, 202418
NCT03917381Solid Tumors · United States, Czechia, Georgia and more2TerminatedApr 1, 2025429

How it is read

Names in the registry

  • “Acasunlimab”, 6 entries
  • “Acasunlimab in combination with docetaxel (in a single expansion cohort)”, 1 entry
  • “Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)”, 1 entry
  • “Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.